BTG.L - BTG International Ltd.

LSE - LSE Delayed Price. Currency in GBp
840.00
0.00 (0.00%)
As of 4:35PM BST. Market open.
Stock chart is not supported by your current browser
Previous Close840.00
Open839.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range839.00 - 840.00
52 Week Range512.50 - 853.00
Volume2,865,005
Avg. Volume1,267,702
Market Cap3.261B
Beta (3Y Monthly)N/A
PE Ratio (TTM)29.47
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • PR Newswire

    Boston Scientific Closes Acquisition of BTG plc.

    MARLBOROUGH, Mass., Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced the completion of its acquisition of BTG plc. (BTG.L) pursuant to the previously announced scheme of arrangement. BTG has three key businesses, the largest of which is its highly-differentiated Interventional Medicine portfolio that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease. "The addition of the BTG Interventional Medicine portfolio reinforces our category leadership strategy and enables us to offer best-in-class technologies, unparalleled clinical evidence and a strengthened commercial infrastructure to support physicians treating some of the most challenging diseases impacting patient health around the world," said Mike Mahoney, chairman and chief executive officer, Boston Scientific.

  • BTG receives Health Canada Medical Device License for the ICEfx™ Cryoablation System
    CNW Group

    BTG receives Health Canada Medical Device License for the ICEfx™ Cryoablation System

    OTTAWA , Aug. 15, 2019 /CNW/ - BTG International Canada Inc., part of the global specialist healthcare company BTG plc (BTG.L), today announced it has received a medical device license from Health Canada for the ICEfx ™ Cryoablation System. Cryotherapy (also known as cryosurgery or cryoablation) is a minimally invasive procedure that involves cooling the tip of a very thin needle to extremely low temperatures using compressed argon gas. Cryotherapy ablation is widely used in patients with prostate cancer, kidney cancer and pain applications.

  • PR Newswire

    Randomized double-blinded study to commence on DigiFab® for kidney injury related to CABG surgery

    PHILADELPHIA, Aug. 5, 2019 /PRNewswire/ -- BTG plc (BTG.L), the global healthcare company, today announced the start of a randomized double-blinded clinical study, initiated by researchers at the University of Maryland School of Medicine (UMSOM), that examines the role of DigiFab® (Digoxin Immune FAB (ovine)) in patients with an elevated risk of acute kidney injury undergoing coronary artery bypass graft (CABG) surgery. Acute kidney injury (AKI) occurs in nearly 30 percent of patients undergoing CABG surgeryi, and AKI often requires patients to undergo dialysis. There are no known therapies that reduce the chance of developing kidney damage after heart surgery.

  • PR Newswire

    Recommendations for Personalised HCC Treatment With Y90 TheraSphere™ Published by an International Multidisciplinary Group

    Supported by comparative Dosisphere data, a phase II multicentric randomised dosimetry trial LONDON , July 23, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), a global healthcare company, today announced consensus ...

  • BTG to Invest in Chinese Medical Isotope Diagnosis and Treatment Company Chengdu New Radiomedicine Technology
    PR Newswire

    BTG to Invest in Chinese Medical Isotope Diagnosis and Treatment Company Chengdu New Radiomedicine Technology

    LONDON , July 16, 2019 /PRNewswire/ -- BTG International Asia Limited, a subsidiary of BTG plc (LSE: BTG) announced today that it has agreed to invest RMB 76million (approximately USD 11million ) in the ...

  • PR Newswire

    NCCN issues first pediatric acute lymphoblastic leukemia guidelines, including use of Voraxaze®

    PHILADELPHIA , July 11, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), the global healthcare company, today highlighted the first publication of National Comprehensive Cancer Network (NCCN) pediatric acute lymphoblastic ...

  • Venous Leg Ulcer Registry Shows Promising Results for Varithena® Use in Wound Healing
    PR Newswire

    Venous Leg Ulcer Registry Shows Promising Results for Varithena® Use in Wound Healing

    BOTHELL, WA , April 29, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), the global specialist healthcare company, today highlighted the VIEW VLU Registry interim study results, presented at the International ...

  • Business Wire

    Trial Finds Patients Receiving CroFab® Antivenom Less Likely to Use Opioids for Pain Control

    BTG plc (BTG.L), the global healthcare company, today announced the publication of a trial, "Antivenom Treatment is Associated with Fewer Patients Using Opioids after Copperhead Envenomation" in the Western Journal of Emergency Medicine (WestJEM). “In a randomized, double-blind, placebo-controlled, clinical trial of CroFab® for treatment of copperhead snakebite, patients that received CroFab® were less likely to use opioids for pain control during recovery,” said Dr. Charles Gerardo, Chief of Emergency Medicine at Duke University and expert in copperhead snake envenomation.

  • PR Newswire

    NHS England Expands Loco-regional Treatment Options for Colorectal Cancer Patients With Metastatic Disease

    LONDON , Feb. 5, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), a global healthcare company, today announced that the NHS Specialised Services Commissioning Committee has agreed that, effective 1 April 2019 ...

  • PR Newswire

    Australian Patient Treated With DC Bead LUMI™, the First Commercially Available Radiopaque Drug-Eluting Bead

    LONDON , January 21, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of an Australian patient with DC Bead LUMI™, a next-generation development ...

  • PR Newswire

    BTG and OMNY Partner to Improve Treatment of Snake Bite Victims

    BTG, the global healthcare company, is partnering with OMNY to improve visibility of inventory data for its antivenom product CroFab® using distributed ledger technology. This makes it important to understand and manage antivenom stock levels. CroFab® is the only FDA-approved product to treat all North American pit viper envenomations in adult and pediatric patients.[ii],[iii] It is proven to control local, systemic, and hematologic effects of envenomation[ii], [iv], * and 95% of patients showed a clinical response 1 hour after initial control[v].

  • PR Newswire

    BTG Announces National Reimbursement for TheraSphere® in France

    BTG plc (BTG.L), a global specialist healthcare company, today announced that the French Ministry of Health and Social Affairs will reimburse TheraSphere® for patients with liver cancer who meet certain criteria. "This reimbursement decision provides access to a new treatment option for some of the estimated 9,600 people diagnosed with liver cancer in France each year[iv]," said Jane Lapon, VP Global Market Access at BTG.

  • Business Wire

    Arizona Patients Successfully Receive the World’s First Bioconvertible IVC Filter Commercially Offered In US

    BTG plc (BTG.L), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter. The BTG Sentry filter is designed to provide protection from Pulmonary Embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen, eliminating the need to retrieve and addressing the typical filter-related complications associated with conventional IVC filters. Dr. Ayad K.M. Agha, Director of Interventional Radiology and an interventional radiologist at Cardiovascular Interventional Radiology Centers in Phoenix, Arizona, who performed the procedure on one of his patients, said: “Traditional IVC filters are sometimes associated with a variety of concerns.

  • PR Newswire

    Boston Scientific Announces Recommended Offer to Acquire BTG plc.

    The transaction has been unanimously approved by the boards of directors of Boston Scientific and BTG. Under the terms of the transaction, holders of BTG's common shares would receive cash consideration of 840 pence per share. The total cash consideration for 100% of BTG's equity is approximately £3.3B, or U.S.$4.2B.

  • Business Wire

    BTG Sentry Bioconvertible IVC Filter 2-year Study Results Show Zero Tilt, Migration, Perforation, Fracture, or Embolization

    BTG plc (BTG.L), the global healthcare company, highlighted the presentation of the two-year results for the SENTRY trial, at the Vascular Interventional Advances (VIVA) conference in Las Vegas. The prospective, multicenter trial of the BTG Sentry, the world’s first bioconvertible IVC filter, found that in addition to providing protection against pulmonary embolism (PE) during the transient risk period, the device also had zero instances of tilt, perforation, migration and embolization through two years of imaging-intensive follow-up. “This long-term data marks a paradigm shift in pulmonary embolism protection and is exactly why we brought the BTG Sentry to market,” said BTG Chief Commercial Officer John Sylvester.

  • Business Wire

    EKOS™ Control Unit 4.0 Simplifies Treatment of Blood Clots

    First commercial units are shipped to Europe

  • PR Newswire

    Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and Appoints George Golumbeski as Chairman

    Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, has today announced that it has licensed exclusive worldwide rights to develop and commercialise BTG945, now CT900, an investigational targeted ovarian cancer drug, from the global specialist healthcare company BTG plc ("BTG", LSE: BTG). CT900 is a targeted therapy that combines targeting folate receptor α (FRα) and inhibiting thymidylate synthase.

  • PR Newswire

    BTG Announces Replacement Policy for Expired CroFab®

    WEST CONSHOHOCKEN, Pa. , Sept. 26, 2018 /PRNewswire/ --   BTG plc (LSE: BTG) today announced a policy for replacement of expired vials of CroFab ® Crotalidae Polyvalent Immune Fab (Ovine), allowing customers ...

  • PR Newswire

    BTG Announces Global Launch of the ICEfx™ Cryoablation System

    LONDON , September 20, 2018 /PRNewswire/ -- The ICEfx™ Cryoablation system is a compact and powerful console, offering predictable, reliable performance with seamless therapy delivery and exceptional ease ...